The JMJD3 demethylase inhibitor, GSK-J1, showed convincing potency in suppressing ovarian cancer by restoring H3K27 methylation at the HER2 oncogene promoter region and then suppressing its transcription (Zhang et al., 2020). Here, ERBB2 is linked to ovarian cancer.